Clinical Vignette
Patient: "Ms. L," 29-year-old marketing director, presenting with cyclical severe mood disturbance, irritability, and functional impairment occurring exclusively in the 7-10 days before her menstrual period.
Chief Concern: "Every month, about a week before my period, I become a different person. I'm rageful, crying over nothing, so anxious I can't function. My husband says he can 'tell by my face' when it's starting. I've nearly lost my job because of outbursts during this time. Then my period starts and within 2 days I feel completely normal. This has been happening for 6 years."
History of Present Illness: Ms. L reports a 6-year history of severe premenstrual symptoms beginning 7-10 days before menses and resolving 2-3 days after onset of menses. During the luteal phase (symptomatic window): (1) Marked affective lability (crying episodes triggered by minimal stimuli, rapid mood swings), (2) Marked irritability/anger (screaming at husband and coworkers over minor issues, road rage), (3) Marked depressed mood (hopelessness, self-deprecation — 'I'm a terrible person'), (4) Marked anxiety (physical tension, panic-like episodes, feeling 'overwhelmed by everything'), (5) Decreased interest in usual activities, (6) Difficulty concentrating ('brain fog'), (7) Fatigue and low energy, (8) Change in appetite (carbohydrate craving), (9) Insomnia, (10) Breast tenderness and bloating, (11) Sense of being overwhelmed/out of control. During the follicular phase (days 4-14 of cycle): she is 'completely herself' — productive, even-tempered, energetic, no symptoms. The cyclicity is ABSOLUTE: symptoms are present luteal phase, absent follicular phase. She has tracked this prospectively for 3 months using a daily symptom diary, confirming the pattern. Functional impairment: written up at work for 2 outbursts during luteal phase, severe marital conflict (husband has considered separation).
Medical History: Regular 28-day menstrual cycles. No hormonal contraception. No thyroid disorder. No other medical conditions.
Mental Status Exam: Interviewed during follicular phase (day 8): affect pleasant, mood 'good — today.' Speech normal. Cognition intact. No irritability, no tearfulness, no anxiety. She reports: 'You wouldn't know anything was wrong with me right now. Come back in 2 weeks and I'll be a different person.' Prospective daily symptom diary reviewed: confirms symptoms exclusively in days 18-28 of cycle, with complete resolution by day 3-4.
Step 1: PMDD DSM-5-TR Criteria
Criterion A: In the majority of menstrual cycles, ≥5 symptoms present in the final week before menses, improve within a few days of menses onset, and are minimal/absent in the week post-menses.
Symptoms in days 18-28, resolve by day 3-4, absent days 4-14. Present in every cycle for 6 years. Confirmed by 3-month prospective daily diary. MET.
Criterion B: ≥1 of the following: (1) marked affective lability, (2) marked irritability/anger, (3) marked depressed mood, (4) marked anxiety/tension.
ALL 4 present: affective lability, irritability/rage, depressed mood, anxiety. MET — all 4.
Criterion C: ≥1 additional symptom to reach total ≥5 with Criterion B: (5) decreased interest, (6) concentration difficulty, (7) fatigue, (8) appetite change, (9) sleep disturbance, (10) overwhelmed/out of control, (11) physical symptoms.
(5) Decreased interest, (6) concentration difficulty, (7) fatigue, (8) appetite change, (9) insomnia, (10) overwhelmed, (11) breast tenderness/bloating. All 7 additional present. MET — total 11/11 symptoms.
Criterion D: Symptoms associated with clinically significant distress or interference with work, social activities, or relationships.
Written up at work. Near job loss. Severe marital conflict. Husband considering separation. MET.
Criterion E: Not exacerbation of another disorder (MDD, PD, PDD, PD).
Complete symptom resolution during follicular phase. MDD would not show this cyclicity. No baseline mood disorder. MET — NOT exacerbation.
Criterion F: Confirmed by prospective daily ratings for ≥2 symptomatic cycles.
3-month prospective daily symptom diary confirms the pattern. MET — prospectively confirmed.
Criterion G: Not attributable to substance or medical condition.
No hormonal contraception. No thyroid disorder. No substance use. MET.
Step 2: PMDD vs. Premenstrual Syndrome (PMS) vs. Premenstrual Exacerbation of MDD
| Feature | PMDD | PMS | Premenstrual Exacerbation of MDD |
|---|---|---|---|
| Mood symptoms | MARKED (severe, dominant) | Mild-moderate (secondary to physical) | Worsening of baseline MDD |
| Functional impairment | Significant | Mild or none | Present at baseline, worsens premenstrually |
| Follicular phase | SYMPTOM-FREE | Symptom-free or mild | Symptoms PERSIST (may be milder) |
| Baseline mood disorder | Absent | Absent | PRESENT (MDD diagnosed) |
| DSM classification | Depressive disorder | Not a DSM diagnosis | Specifier of existing MDD |
Prospective Rating Requirement
DSM-5-TR REQUIRES prospective daily ratings for ≥2 symptomatic cycles (Criterion F) before PMDD can be diagnosed. Retrospective report alone is insufficient because of recall bias. Ms. L's 3-month daily diary satisfies this requirement.
Diagnostic Formulation
Diagnostic Conclusion
Premenstrual Dysphoric Disorder (N94.3): All DSM-5-TR criteria met. 11/11 symptoms present. Prospectively confirmed over 3 cycles. Severe functional impairment. Treatment: (1) First-line: SSRI (fluoxetine, sertraline) — can be given continuously OR only during luteal phase (luteal-phase dosing: effective and reduces total medication exposure). (2) If SSRI insufficient: oral contraceptive (drospirenone/ethinyl estradiol combination — some evidence for PMDD). (3) CBT: cognitive restructuring of premenstrual catastrophizing, behavioral strategies for luteal-phase management. (4) Lifestyle: regular exercise, calcium supplementation (evidence for mild symptom reduction).
Teaching Points
- PMDD is classified as a DEPRESSIVE DISORDER in DSM-5-TR, reflecting the prominence of mood symptoms. This placement is significant: PMDD is a psychiatric diagnosis with biological underpinnings, not simply 'severe PMS.' The distinction matters for treatment (psychiatric interventions are indicated) and for legitimacy (reduces dismissiveness toward women's mood disturbances).
- The PROSPECTIVE daily rating requirement (Criterion F) is unique to PMDD among DSM-5-TR diagnoses. No other diagnosis requires prospective symptom tracking for confirmation. This requirement exists because retrospective report of premenstrual symptoms has been shown to be unreliable due to confirmation bias and cultural expectations.
- SSRIs are first-line pharmacotherapy for PMDD and can be used in LUTEAL-PHASE DOSING: taken only during the symptomatic 10-14 days before menses, then discontinued when menses begins. This intermittent dosing is effective because SSRIs' effect on PMDD symptoms occurs more rapidly (within days) than their effect on MDD (which requires weeks). The mechanism may involve neurosteroid modulation rather than, or in addition to, serotonin reuptake inhibition.
- The pathophysiology of PMDD involves ABNORMAL SENSITIVITY TO NORMAL HORMONAL CHANGES. Women with PMDD have normal hormone levels; their central nervous system responds differently to the normal progesterone-allopregnanolone fluctuations of the luteal phase. This explains why symptom profiles are identical to MDD/GAD but limited to the luteal phase.
- PMDD affects approximately 3-8% of reproductive-age women (in contrast to PMS, which affects 20-40%). The distinction between PMDD and PMS is severity and symptom domain: PMDD requires MARKED mood symptoms with functional impairment. PMS typically involves mild-to-moderate physical symptoms (bloating, breast tenderness) with minimal mood disturbance.